Compare · BBNX vs WST
BBNX vs WST
Side-by-side comparison of Beta Bionics Inc. (BBNX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.59B, about 36.5x BBNX ($618.1M).
- Over the past year, BBNX is down 26.9% and WST is up 48.2% - WST leads by 75.1 points.
- BBNX has been more active in the news (17 items in the past 4 weeks vs 5 for WST).
- WST has more recent analyst coverage (17 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- West Pharmaceutical Services Inc.
- Price
- $14.19+2.01%
- $331.64+3.63%
- Market cap
- $618.1M
- $22.59B
- 1M return
- +47.20%
- +1.74%
- 1Y return
- -26.89%
- +48.16%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 17
- 5
- Recent ratings
- 16
- 17
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest BBNX
- Director Jones Christy sold $39,354 worth of shares (2,811 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 27,400 units (SEC Form 4)
- Chief Commercial Officer Hopman Mark sold $3,385 worth of shares (275 units at $12.31) as part of a pre-agreed trading plan, decreasing direct ownership by 0.21% to 130,612 units (SEC Form 4)
- Chief Product Officer Mensinger Mike sold $55,194 worth of shares (4,378 units at $12.61), decreasing direct ownership by 2% to 184,415 units (SEC Form 4) (tax liability)
- Chief Commercial Officer Hopman Mark sold $67,183 worth of shares (5,329 units at $12.61), decreasing direct ownership by 4% to 130,887 units (SEC Form 4) to satisfy withholding tax
- President & CEO Saint Sean sold $212,707 worth of shares (16,872 units at $12.61), decreasing direct ownership by 4% to 420,937 units (SEC Form 4) to cover taxes
- Chief Medical Officer Russell Steven Jon sold $53,227 worth of shares (4,222 units at $12.61), decreasing direct ownership by 2% to 173,849 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Feider Stephen sold $84,165 worth of shares (6,676 units at $12.61), decreasing direct ownership by 4% to 166,053 units (SEC Form 4) to satisfy tax liability
- Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
- Director Palasis Maria was granted 16,965 shares, increasing direct ownership by 136% to 29,397 units (SEC Form 4)
- Director Michel Gerard J was granted 16,965 shares, increasing direct ownership by 103% to 33,509 units (SEC Form 4)
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)